Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated July 11, 2023 (updated on January 30, 2026), Akums Drugs and Pharmaceuticals has informed that on September 02, 2026, the Company has received an ESG rating of ‘65’ for the Financial Year 2025-26 from NSE Sustainability Ratings & Analytics (‘NSE Sustainability’), a subsidiary of NSE Indices and a registered ESG Rating Provider. The company has informed that it has not engaged NSE Sustainability for ESG Rating and they have voluntarily assigned the aforesaid ESG Rating on the basis of publicly available information. The link of the ESG rating is https://www.nse-esgrating.com/esg-ratings/552?fiscalYear=2024-2025.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1904.00 |
| Dr. Reddys Labs. | 1155.00 |
| Cipla | 1389.00 |
| Lupin | 2135.00 |
| Zydus Lifesciences | 1135.00 |
| View more.. | |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: